ASCVD Management Using CCTA in Prostate Cancer Patients on ADT

StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Dec 2026 → Jul 2027
See other at-risk trials from Indiana University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2026 to Jul 2027
    • Study completion pushed from Dec 2027 to Jul 2028
    • Eligibility criteria expanded, about 14 words
  2. Site contacts updated at 3 of 3 sites
    • Collaborators revised (3)
    v10
  3. Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: Dec 2026 to Dec 2027
    v9
  4. Site contacts updated at 3 of 3 sitesv8
  5. Study sites: 1 to 3v7
Show 5 earlier versionsHide 5 earlier versions
  1. Site contact updated
    • Collaborators revised (3)
    v6
  2. Primary completion date: Dec 31, 2025 to Dec 2025
    • Study completion date: Dec 31, 2026 to Dec 2026
    • Start date changed from estimate of Jan 2024 to Dec 15, 2023
    v5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 31, 2023 to Jan 2024
    • Site details revised
    v4
  4. Start date: Aug 1, 2023 to Oct 31, 2023
    • Site contact updated
    • Study title expanded, about 3 words
    v3
  5. Start date: Jun 1, 2023 to Aug 1, 2023v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized pilot study of Coronary CT Angiography (CCTA) for coronary atherosclerosis vs. Usual Care in patients with prostate cancer who are either planning to begin, or are currently taking androgen deprivation therapy (ADT) .
Trial Details
NCT Number NCT05879913
Lead Sponsor Indiana University
Collaborators: National Comprehensive Cancer Network, Pfizer, Sumitomo Pharma America, Inc.
Conditions
(from sponsor)		 Prostate Cancer
Related terms Coronary Artery Disease, Prostatic Neoplasms
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov